Linked Life Data

21646351

Source:http://linkedlifedata.com/resource/pubmed/id/21646351

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21646351rdf:typepubmed:Citationlld:pubmed
pubmed-article:21646351lifeskim:mentionsumls-concept:C0302592lld:lifeskim
pubmed-article:21646351lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:21646351lifeskim:mentionsumls-concept:C1326912lld:lifeskim
pubmed-article:21646351lifeskim:mentionsumls-concept:C1533646lld:lifeskim
pubmed-article:21646351lifeskim:mentionsumls-concept:C2720171lld:lifeskim
pubmed-article:21646351lifeskim:mentionsumls-concept:C1880177lld:lifeskim
pubmed-article:21646351lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:21646351pubmed:issue29lld:pubmed
pubmed-article:21646351pubmed:dateCreated2011-7-19lld:pubmed
pubmed-article:21646351pubmed:abstractTextMicroRNAs are a class of noncoding RNAs that are ~22 nucleotides in length. MicroRNAs have been shown to play important roles in cell differentiation and in cancer. Recently, studies have shown that miR-372 is tumorigenic in human reproductive system cancers. However, we provide evidence that miR-372 acts as a tumor suppressor gene in cervical carcinoma. miR-372 was found down-regulated in cervical carcinoma tissues as compared with adjacent normal cervical tissues. Growth curve and FACS assays indicated that ectopic expression of miR-372 suppressed cell growth and induced arrest in the S/G? phases of cell cycle in HeLa cells. We used bioinformatic predictions to determine that CDK2 and cyclin A1 were possible targets of miR-372 and confirmed this prediction using a fluorescent reporter assay. Taken together, these findings indicate that an anti-oncogenic role of miR-372 may be through control of cell growth and cell cycle progression by down-regulating the cell cycle genes CDK2 and cyclin A1.lld:pubmed
pubmed-article:21646351pubmed:languageenglld:pubmed
pubmed-article:21646351pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21646351pubmed:citationSubsetIMlld:pubmed
pubmed-article:21646351pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21646351pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21646351pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21646351pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21646351pubmed:statusMEDLINElld:pubmed
pubmed-article:21646351pubmed:monthJullld:pubmed
pubmed-article:21646351pubmed:issn1083-351Xlld:pubmed
pubmed-article:21646351pubmed:authorpubmed-author:XuZ CZClld:pubmed
pubmed-article:21646351pubmed:authorpubmed-author:TangHuaHlld:pubmed
pubmed-article:21646351pubmed:authorpubmed-author:LiuMinMlld:pubmed
pubmed-article:21646351pubmed:authorpubmed-author:JiaWei-HuaWHlld:pubmed
pubmed-article:21646351pubmed:authorpubmed-author:YangQianQlld:pubmed
pubmed-article:21646351pubmed:authorpubmed-author:WangXing-HuaX...lld:pubmed
pubmed-article:21646351pubmed:authorpubmed-author:LiYi-XuanYXlld:pubmed
pubmed-article:21646351pubmed:authorpubmed-author:TianRui-QingR...lld:pubmed
pubmed-article:21646351pubmed:authorpubmed-author:HouLi-JuanLJlld:pubmed
pubmed-article:21646351pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21646351pubmed:day22lld:pubmed
pubmed-article:21646351pubmed:volume286lld:pubmed
pubmed-article:21646351pubmed:ownerNLMlld:pubmed
pubmed-article:21646351pubmed:authorsCompleteYlld:pubmed
pubmed-article:21646351pubmed:pagination25556-63lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:meshHeadingpubmed-meshheading:21646351...lld:pubmed
pubmed-article:21646351pubmed:year2011lld:pubmed
pubmed-article:21646351pubmed:articleTitleMicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis.lld:pubmed
pubmed-article:21646351pubmed:affiliationTianjin Life Science Research Center and Basic Medical School, Tianjin Medical University, Tianjin 300070, China.lld:pubmed
pubmed-article:21646351pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21646351pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:1017entrezgene:pubmedpubmed-article:21646351lld:entrezgene
entrez-gene:8900entrezgene:pubmedpubmed-article:21646351lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21646351lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21646351lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21646351lld:entrezgene